$CNSP
CNS Pharmaceuticals, Inc.

2024 Q4 Form 10-Q Financial Statement

#000168316824008125 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.384M
YoY Change 23.2%
% of Gross Profit
Research & Development $4.245M
YoY Change 24.47%
% of Gross Profit
Depreciation & Amortization $750.00
YoY Change -76.42%
% of Gross Profit
Operating Expenses $5.629M
YoY Change 24.15%
Operating Profit -$5.629M
YoY Change 24.15%
Interest Expense $22.97K
YoY Change 1149.73%
% of Operating Profit
Other Income/Expense, Net $22.97K
YoY Change 107.99%
Pretax Income -$5.606M
YoY Change 23.95%
Income Tax
% Of Pretax Income
Net Earnings -$5.606M
YoY Change 23.95%
Net Earnings / Revenue
Basic Earnings Per Share -$0.25
Diluted Earnings Per Share -$0.25
COMMON SHARES
Basic Shares Outstanding 57.49M shares 32.15M shares
Diluted Shares Outstanding 22.18M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.973M
YoY Change 666.66%
Cash & Equivalents $6.973M
Short-Term Investments
Other Short-Term Assets $415.0K
YoY Change -63.99%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.388M
YoY Change 258.32%
LONG-TERM ASSETS
Property, Plant & Equipment $2.802K
YoY Change -19.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $18.37K
YoY Change -93.01%
Total Long-Term Assets $21.18K
YoY Change -92.05%
TOTAL ASSETS
Total Short-Term Assets $7.388M
Total Long-Term Assets $21.18K
Total Assets $7.409M
YoY Change 218.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.026M
YoY Change -0.03%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $31.19K
YoY Change -25.56%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.057M
YoY Change -0.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.057M
Total Long-Term Liabilities $0.00
Total Liabilities $4.057M
YoY Change -0.29%
SHAREHOLDERS EQUITY
Retained Earnings -$81.25M
YoY Change 26.57%
Common Stock $33.45K
YoY Change 695.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.352M
YoY Change
Total Liabilities & Shareholders Equity $7.409M
YoY Change 218.26%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$5.606M
YoY Change 23.95%
Depreciation, Depletion And Amortization $750.00
YoY Change -76.42%
Cash From Operating Activities -$6.800M
YoY Change 101.56%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 12.28M
YoY Change 128368.1%
NET CHANGE
Cash From Operating Activities -6.800M
Cash From Investing Activities 0.000
Cash From Financing Activities 12.28M
Net Change In Cash 5.482M
YoY Change -262.86%
FREE CASH FLOW
Cash From Operating Activities -$6.800M
Capital Expenditures $0.00
Free Cash Flow -$6.800M
YoY Change 101.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9823884 usd
us-gaap Operating Expenses
OperatingExpenses
11701895 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5628906 usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001729427
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6973124 usd
CY2024Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
26932 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
388042 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
7388098 usd
CY2024Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
18373 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2802 usd
CY2024Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
21175 usd
CY2024Q3 us-gaap Assets
Assets
7409273 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4025742 usd
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
31187 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4056929 usd
CY2024Q3 us-gaap Liabilities
Liabilities
4056929 usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
33446 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
84567236 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-81248338 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
3352344 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7409273 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1383913 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1123268 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4244993 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3410572 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7791967 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
5628906 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
4533840 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4533840 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-11701895 usd
CY2024Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
25230 usd
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
12883 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
33806 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
2258 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1838 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
13346 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22972 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11045 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
20460 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4522795 usd
us-gaap Net Income Loss
NetIncomeLoss
-11681435 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-54.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.54
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-54.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.54
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22180874 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83542 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7581312 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22180874 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83542 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7581312 shares
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
usd
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39126
dei Entity Registrant Name
EntityRegistrantName
CNS Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2318545
dei Entity Address Address Line1
EntityAddressAddressLine1
2100 West Loop South
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 900
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77027
dei City Area Code
CityAreaCode
800
dei Local Phone Number
LocalPhoneNumber
946-9185
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
CNSP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
57486706 shares
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
548721 usd
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
202859 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
839590 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1591170 usd
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
104750 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4933 usd
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
109683 usd
CY2023Q4 us-gaap Assets
Assets
1700853 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5832162 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
300806 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6132968 usd
CY2023Q4 us-gaap Liabilities
Liabilities
6132968 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33446403 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33446403 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
124306 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
124306 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
124 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
65134664 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-69566903 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4432115 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1700853 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3909928 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3661853 usd
us-gaap Operating Expenses
OperatingExpenses
13485737 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-13485737 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
20685 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
10924 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9761 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5605934 usd
us-gaap Net Income Loss
NetIncomeLoss
-13475976 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-202.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-202.48
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66553 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66553 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4432115 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3330998 usd
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
12405 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
202933 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3544748 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-4430527 usd
CY2024Q2 CNSP Common Stock Issued For Cash And Warrants Net
CommonStockIssuedForCashAndWarrantsNet
2424413 usd
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
8921 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
234345 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2530753 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-4293601 usd
CY2024Q3 CNSP Common Stock Issued For Cash And Warrants Net
CommonStockIssuedForCashAndWarrantsNet
12383798 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
271779 usd
CY2024Q3 CNSP Common Stock Issued For License Agreement Value
CommonStockIssuedForLicenseAgreementValue
596302 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5605934 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
3352344 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8132856 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
609 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
290313 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4931947 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
3491831 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1969107 usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
725059 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
289670 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4021234 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2454433 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
132851 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
194759 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4522795 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1740752 usd
us-gaap Net Income Loss
NetIncomeLoss
-11681435 usd
us-gaap Net Income Loss
NetIncomeLoss
-13475976 usd
us-gaap Share Based Compensation
ShareBasedCompensation
709057 usd
us-gaap Share Based Compensation
ShareBasedCompensation
774742 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
596302 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 usd
us-gaap Depreciation
Depreciation
2321 usd
us-gaap Depreciation
Depreciation
3181 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
190 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-757 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-537925 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1577015 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1806420 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-483397 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11642440 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11603678 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1744 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1744 usd
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
56750 usd
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
-0 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
269619 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
368064 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
21326 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
725668 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18371886 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2101958 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18066843 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2459562 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
6424403 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-9145860 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
548721 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10055407 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6973124 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
909547 usd
us-gaap Interest Paid Net
InterestPaidNet
13346 usd
us-gaap Interest Paid Net
InterestPaidNet
10924 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CNSP Reclassification Of Deferred Offering Costs To Equity
ReclassificationOfDeferredOfferingCostsToEquity
232677 usd
CNSP Reclassification Of Deferred Offering Costs To Equity
ReclassificationOfDeferredOfferingCostsToEquity
0 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_80C_eus-gaap--NatureOfOperations_zrfi0Egc6tY3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 – <span id="xdx_829_zgW1HO8E0sI3">Nature of Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CNS Pharmaceuticals, Inc. (“we”, “our”, the “Company”) is a clinical pharmaceutical company organized as a Nevada corporation on July 27, 2017 to focus on the development of anti-cancer drug candidates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 25, 2022, the stockholders of the Company approved an amendment to the Company’s amended and restated articles of incorporation (the “Amendment”) to effect the reverse stock split at a ratio in the range of 1-for-2 to 1-for-30. The reverse stock split became effective on November 28, 2022 on a <span id="xdx_903_eus-gaap--StockholdersEquityReverseStockSplit_c20221127__20221128_zNzAAAZLplh7" title="Reverse stock split">1-for-30</span> basis without any change in the par value per share, which remained at $0.001. The reverse stock split has been retroactively adjusted throughout these financial statements and footnotes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 30, 2024, the stockholders of the Company approved an amendment to the Company’s amended and restated articles of incorporation (the “Amendment”) to effect the reverse stock split at a ratio in the range of 1-for-2 to 1-for-50. The reverse stock split became effective on June 4, 2024 on a <span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20240603__20240604_zsgvEGWuNBf1" title="Reverse stock split">1-for-50</span> basis without any change in the par value per share, which remained at $0.001. The reverse stock split has been retroactively adjusted throughout these financial statements and footnotes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2022Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-30
CY2024Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-50
CY2024Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
6723124 usd
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-30
CY2024Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-50
CNSP Fair Value Of Common Stock On Measurement Date
FairValueOfCommonStockOnMeasurementDate
$12.65 to $12.93 per share
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y6M29D
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
cnsp-20240930_cal.xml Edgar Link unprocessable
0001683168-24-008125-index-headers.html Edgar Link pending
0001683168-24-008125-index.html Edgar Link pending
0001683168-24-008125.txt Edgar Link pending
0001683168-24-008125-xbrl.zip Edgar Link pending
cnsp-20240930.xsd Edgar Link pending
cns_ex3101.htm Edgar Link pending
cns_ex3102.htm Edgar Link pending
cns_ex3201.htm Edgar Link pending
cns_ex3202.htm Edgar Link pending
cns_i10q-093024.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
cnsp-20240930_def.xml Edgar Link unprocessable
cnsp-20240930_lab.xml Edgar Link unprocessable
cnsp-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cns_i10q-093024_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending